Synribo (Omacetaxine)

Homoharringtonine is a medicine used to treat a type of leukemia called myeloid leukemia. It works by stopping cancer cells from growing. It's often given as a powder that is mixed with food.

Brand names:Synribo
Medication

What people taking Synribo (Omacetaxine) report

Every report comes from a Lived member, sent anonymously.

Have you tried Synribo (Omacetaxine) for CML (Chronic Myeloid Leukemia)?

NameHow it went

About Synribo (Omacetaxine)

What It's For

Omacetaxine is an injectable chemotherapy medicine for chronic myeloid leukemia (CML), a blood cancer in which the bone marrow makes too many white blood cells. It is a purified form of homoharringtonine, a natural compound from Cephalotaxus evergreen trees. In the US it was sold under the brand name Synribo, which the FDA now lists as discontinued, so anyone considering it should ask the care team whether it can still be obtained. Its approval is narrow. It is for adults whose CML is in the chronic phase (the earlier, more stable stage, when fewer than 10% of cells in the blood and bone marrow are immature blast cells) or the accelerated phase (a more advanced stage, with 10% to 19% blasts), and whose disease has stopped responding to, or who could not tolerate, at least two tyrosine kinase inhibitors (TKIs). TKIs are the daily pills, such as imatinib, dasatinib and nilotinib, that are the main treatment for CML. It is not approved for the blast phase of CML or for children. Newer TKIs, including Scemblix (asciminib) and Iclusig (ponatinib), are also approved for chronic phase CML after earlier TKIs. Homoharringtonine has been studied in other blood cancers, such as acute myeloid leukemia, but those uses are not approved in the US.

How It Works

Cells constantly build proteins, and some of the proteins leukemia cells depend on are short-lived and must be replaced quickly. Omacetaxine slows protein production by binding to the ribosome, the cell's protein-building machinery. In laboratory studies this lowered levels of BCR-ABL, the abnormal protein that drives CML, and of Mcl-1, a protein that helps cancer cells avoid dying. With less of these proteins, leukemia cells are more likely to die. Unlike TKIs, omacetaxine does not work by attaching to BCR-ABL itself, which is why it was developed for disease that no longer responds to those pills. In animal studies it was active against CML carrying T315I, a mutation that makes many TKIs ineffective. Its full mechanism is not understood. Because healthy blood-forming cells also rely on steady protein production, the medicine lowers normal blood counts too, which explains its main side effects.

Dosage & Administration

Omacetaxine is given as an injection under the skin (a subcutaneous injection), twice a day about 12 hours apart. The dose is calculated from body size. Treatment runs in 28-day cycles. In the first stage, called induction, injections are given for 14 days of each cycle until blood counts respond. After that, maintenance cycles use 7 days of injections every 28 days, continued for as long as the person is benefiting. Cycles are often delayed or shortened when blood counts drop too low. Injections may be given in a clinic, or at home by the patient or a caregiver after training. Because it is a cytotoxic (cell-killing) drug, home use involves syringes prepared to the person's dose, disposable gloves and eye protection while handling it, rotating injection sites, and a biohazard container for used needles that goes back to the clinic or pharmacy. If a dose is missed, skip it and give the next one at the usual time; do not give two injections to make up. If the medicine gets on the skin or in the eyes, wash the skin with soap and water or flush the eyes with water, then call the care team right away. Call them right away too if too much was injected or someone swallowed it.

Side Effects

Low blood counts are expected, and they are often severe. In clinical trials, most people developed seriously low platelets (cells that help blood clot) and neutrophils (white blood cells that fight infection), and many had anemia (low red blood cells), which can cause tiredness and shortness of breath. Other common effects include diarrhea, nausea, fatigue, weakness, fever, redness or bruising where the injection is given, joint pain, headache and hair loss. Fatigue can be enough to make driving or using machinery unsafe. Low white cell counts make infections more likely and potentially life-threatening, so fever, chills or body aches should be reported to the care team right away, as should new shortness of breath or unusual exhaustion. Low platelets raise the risk of bleeding: unusual bleeding, easy bruising, or blood in the urine or stool also needs a prompt call. In trials, about 2% of people died from bleeding in the brain. Sudden confusion, slurred speech or vision changes can be signs of bleeding in the brain and need emergency care right away (call 911). Nausea, diarrhea or vomiting that does not settle, or a rash that is severe or getting worse, should also be reported.

Interactions & Warnings

Omacetaxine has no listed contraindications, but several precautions shape how it is used. Medicines that make bleeding more likely, including blood thinners (anticoagulants), aspirin and anti-inflammatory pain relievers such as ibuprofen and naproxen, should be avoided when the platelet count is below 50,000 per microliter, a level the blood tests will show. Anyone planning dental work or surgery should tell the care team in advance, because low platelets affect bleeding. The care team should know about all other medicines and supplements. The medicine can raise blood sugar, sometimes to dangerous levels. People with diabetes or risk factors for it need more frequent glucose checks, and poorly controlled diabetes should be brought under control before treatment starts. Omacetaxine can harm a developing baby. A pregnancy test is recommended before starting. Women who could become pregnant should use effective birth control during treatment and for 6 months after the last dose, and men with partners who could become pregnant should do so for 3 months after. Breastfeeding is not recommended during treatment or for 2 weeks after. Animal studies suggest it may reduce male fertility. People 65 and older were more likely to have serious side effects, especially low blood counts.

What to Expect

Treatment involves frequent blood tests: complete blood counts weekly during induction and the first maintenance cycles, then about every two weeks. These results decide whether the next cycle starts on time and how many injection days it includes, so schedules often shift. In the main trials most people had at least one delayed cycle. Omacetaxine was tested in people whose CML had already resisted several treatments, and responses were limited. In chronic phase, nearly 1 in 5 people (14 of 76) had a major cytogenetic response, meaning the share of bone marrow cells carrying the Philadelphia chromosome (the genetic change behind CML) fell to 35% or less. These responses appeared after about 3.5 months on average, and half of them lasted about a year or longer. In accelerated phase, about 1 in 7 people (5 of 35) had their blood counts return to near normal, for a median of about 5 months. Without a comparison group, it is hard to know how it measures against other options. The care team weighs whether it is still helping against how well blood counts and side effects are tolerated.

Questions to Ask Your Doctor

  1. 1.Is omacetaxine still available to me now that Synribo is discontinued, and how does it compare with options such as asciminib or ponatinib for my situation?
  2. 2.What response are we looking for, and how will we know after a few cycles whether it is working?
  3. 3.Can I or a caregiver give the injections at home, and what training and supplies would we need?
  4. 4.Which pain relievers are safe for me while my platelets are low, and who should I call after hours about fever or bleeding?
  5. 5.How often will my blood sugar be checked, and what should I do if I have diabetes?

Last reviewed • Oct 2026

Educational content, not medical advice.